Patents by Inventor Alfred Rupprechter

Alfred Rupprechter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quantification of misfolded TNFR2:Fc
    Patent number: 9598718
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 21, 2017
    Assignee: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christoph Posch, Hansjorg Toll, Robert Mayer
  • QUANTIFICATION OF MISFOLDED TNFR2:FC
    Publication number: 20160017403
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Application
    Filed: August 8, 2014
    Publication date: January 21, 2016
    Applicant: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christopher Posch, Hansjorg Toll, Robert Mayer
  • Quantification of misfolded TNFR2:Fc
    Patent number: 9182410
    Abstract: The present invention is directed to methods for determining the relative amount of wrongly disulphide bridged TNFR2:Fc in a sample of TNFR2:Fc, a fusion protein which is used in a variety of therapeutic applications. In addition, the invention pertains to a method for purifying TNFR2:Fc using said method for determining the percentage of wrongly disulphide bridged TNFR2:Fc, and to TNFR2:Fc compositions obtained thereby.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: November 10, 2015
    Assignee: Sandoz AG
    Inventors: Alfred Rupprechter, Michael Fuchs, Johann Holzmann, William Lamanna, Christoph Posch, Hansjorg Toll, Robert Mayer